ATBAD patients were identified from electronic medical records between 2009 and 2019. The 5 year overall and
aortic-disease free survival rates were analyzed and compared between the two groups.
RESULTS: Of the 40 enrolled patients, 27 (67.5%) received
TEVAR and 13 (32.5%) received OMT. The baseline characteristics of the two groups were not significantly different. Kaplan‒Meier survival curve showed that the 5 year overall survival and 5 year
aortic-disease free survival of the
TEVAR group were better than those of the OMT group. The Cox proportional hazard model with unadjusted risk showed an 83.0% decrease in 5 year overall mortality (HR, 0.17; 95% CI, 0.05-0.56) and a lower
aortic-disease related risk (HR, 0.08; 95% CI, 0.02-0.39) in
TEVAR group compared to OMT group. After adjusted for age, gender, smoking, drinking and comorbidities (
diabetes mellitus,
hypertension and
coronary artery diseases), the hazard ratio of 5 year overall mortality was 78.0% lower (HR, 0.22; 95% CI, 0.06.0.81) and the risk of
aortic-disease related mortality was 93.0% lower (HR, 0.07; 95% CI, 0.01-0.61) in
TEVAR group compared to OMT group. In the cohort stratified by age, sex, the risk of the 5 year overall or
aortic-disease related mortality in
TEVAR group was relatively reduced compared to OMT group.
CONCLUSIONS: